A Phase 2 Randomized Trial of the Combination of Ridaforolimus and Exemestane, Compared to Ridaforolimus, Dalotuzumab and Exemestane in High Proliferation, Estrogen Receptor Positive Breast Cancer Patients
Latest Information Update: 12 May 2022
At a glance
- Drugs Dalotuzumab (Primary) ; Ridaforolimus (Primary) ; Exemestane
- Indications Advanced breast cancer
- Focus Therapeutic Use
- Sponsors Merck Sharp & Dohme; Merck Sharp & Dohme Corp.
- 21 Mar 2019 Czech Republic was planned location as per European Clinical Trials Database record.
- 21 Mar 2019 Status changed to completed.
- 15 Mar 2019 This trial has been completed in United Kingdom, according to European Clinical Trials Database.